Valeo Financial Advisors LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 6.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,519 shares of the healthcare product maker’s stock after purchasing an additional 1,238 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Abbott Laboratories were worth $1,869,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cresset Asset Management LLC increased its position in shares of Abbott Laboratories by 20.7% during the second quarter. Cresset Asset Management LLC now owns 29,187 shares of the healthcare product maker’s stock valued at $2,455,000 after acquiring an additional 5,012 shares during the last quarter. Cadinha & Co. LLC raised its holdings in Abbott Laboratories by 0.9% during the third quarter. Cadinha & Co. LLC now owns 18,841 shares of the healthcare product maker’s stock worth $1,576,000 after purchasing an additional 166 shares in the last quarter. Clear Creek Financial Management LLC acquired a new stake in Abbott Laboratories during the second quarter worth approximately $240,000. Lenox Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 58.1% during the 3rd quarter. Lenox Wealth Management Inc. now owns 1,154 shares of the healthcare product maker’s stock worth $96,000 after buying an additional 424 shares during the last quarter. Finally, AE Wealth Management LLC lifted its position in shares of Abbott Laboratories by 7.8% during the 3rd quarter. AE Wealth Management LLC now owns 47,096 shares of the healthcare product maker’s stock worth $3,941,000 after buying an additional 3,401 shares during the last quarter. 73.61% of the stock is owned by institutional investors.

Abbott Laboratories stock traded down $0.29 during midday trading on Friday, hitting $90.44. 2,955,815 shares of the company’s stock were exchanged, compared to its average volume of 4,670,949. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.12 and a current ratio of 1.54. The stock has a market cap of $162.45 billion, a price-to-earnings ratio of 43.90, a price-to-earnings-growth ratio of 2.36 and a beta of 1.12. Abbott Laboratories has a 12-month low of $68.80 and a 12-month high of $92.45. The firm’s 50 day simple moving average is $86.80 and its 200 day simple moving average is $84.76.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $0.95 EPS for the quarter, meeting analysts’ consensus estimates of $0.95. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.34%. The business had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $8.26 billion. During the same period in the prior year, the company earned $0.81 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. On average, equities research analysts forecast that Abbott Laboratories will post 3.61 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 1.59%. The ex-dividend date is Tuesday, January 14th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.32. Abbott Laboratories’s payout ratio is 44.44%.

A number of research analysts recently commented on ABT shares. Wells Fargo & Co increased their target price on shares of Abbott Laboratories from $97.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday. Evercore ISI cut shares of Abbott Laboratories from an “outperform” rating to an “in-line” rating in a research report on Thursday, January 2nd. UBS Group boosted their price target on shares of Abbott Laboratories from $99.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday. ValuEngine lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Guggenheim lowered Abbott Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $95.20.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

See Also: What is a resistance level?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.